Rocket Pharmaceuticals, Inc. (RCKT)
NASDAQ: RCKT · Real-Time Price · USD
7.43
+0.29 (3.99%)
Apr 24, 2025, 4:00 PM EDT - Market closed
Rocket Pharmaceuticals Stock Forecast
RCKT's stock price has decreased by -68.63% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 10 analysts with 12-month price forecasts for Rocket Pharmaceuticals stock have an average target of 44.1, with a low estimate of 15 and a high estimate of 65. The average target predicts an increase of 493.94% from the current stock price of 7.43.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Rocket Pharmaceuticals stock from 10 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 5 | 5 | 5 | 4 | 4 |
| Buy | 5 | 5 | 5 | 4 | 5 | 5 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 10 | 11 | 11 | 10 | 10 | 10 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Needham | Needham | Strong Buy Reiterates $42 | Strong Buy | Reiterates | $42 | +465.66% | Apr 9, 2025 |
| BMO Capital | BMO Capital | Buy Initiates $50 | Buy | Initiates | $50 | +573.40% | Mar 12, 2025 |
| Scotiabank | Scotiabank | Buy Maintains $51 → $52 | Buy | Maintains | $51 → $52 | +600.34% | Mar 3, 2025 |
| Goldman Sachs | Goldman Sachs | Hold Maintains $29 → $15 | Hold | Maintains | $29 → $15 | +102.02% | Mar 3, 2025 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $39 → $36 | Strong Buy | Maintains | $39 → $36 | +384.85% | Mar 3, 2025 |
Financial Forecast
Revenue This Year
n/a
from 803.41M
Revenue Next Year
n/a
EPS This Year
-2.42
from -2.73
EPS Next Year
-1.66
from -2.42
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 233.1M | 562.9M | 1.2B | ||
| Avg | 48.7M | 146.3M | 434.2M | ||
| Low | n/a | 7.3M | 18.0M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -71.0% | 1,057.1% | 688.8% | ||
| Avg | -93.9% | 200.7% | 196.8% | ||
| Low | - | -85.0% | -87.7% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -1.44 | -0.04 | 2.32 | ||
| Avg | -2.42 | -1.66 | 0.13 | ||
| Low | -3.30 | -2.46 | -1.78 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.